Global Metabolomics Market Report 2013 - Forecasts to 2017
News Jan 15, 2014
Research and Markets has announced the addition of the "Global Metabolomics Market Report 2013 - Forecasts to 2017" report to their offering.
Over the last decade, genomics and proteomics have been used as key tools to discover potential drug targets and to better understand the complexities of biology. To balance research in these areas, metabolomics, a new science is evolving for analyzing the basic metabolic changes taking place in a living organism. Metabolomics is thus an emerging concept which refers to the systematic study of the distinctive chemical fingerprints generated in a particular cellular process.
Metabolomics Market - Analysis of Global Technology, Application Trends and Landscape 2012-2017 report covers the market by disease indications along with the applications and metabolite profiling for biomarker discovery applications. In addition, it also includes the factors driving and restraining the market and covers the market scenario in the U.S., Europe, Asia and the Rest of the World (ROW). This report will provide the company profiles of key companies along with the competitive analysis.
The Global Metabolomics market is showing a double digit growth (CAGR 35%) due to supportive factors such as, (i) increased willingness of biotechnology and pharma companies to adopt metabolomics concept to drive R&D activity within the industry, (ii) rapid growth of metabolomics data analysis softwares and solutions, and (iii) the advancement of analytical technologies. Metabolomics is used in the identification of new biomarkers, which indicate a change in the physiological state of a cell or tissue. Biomarker screening is important in the process of new drug discovery, and is also a key in vitro diagnostics tool. Additionally it is also being used for environmental toxicology screening. While, there are major concerns of this market such as the validation challenges, the positive aspects may very well offset the market restraints to aid the market grow at an exceptional rate.
The report also profiles leading participants of this industry with their recent developments and other strategic industry activities. These include: Metabolon Inc (U.S.), Metanomics (Germany), Metabolomic Technologies Inc. (U.S.), Human Metabolome Technologies (Japan), Beckman Coulter(U.S.), Agilent Technologies Inc (U.S.), Bruker Corporation (U.S.), Waters Corporation (U.S.), Biocrates Lifesciences (Austria), Chenomx Inc (Canada), Eisai co. ltd (Japan), Nextgen Metabolomics (U.S.), Phenomenome Discoveries Inc. (Canada) and Metabolomic Discoveries (Germany).
Key Topics Covered:
2. Executive Summary
3. Metabolomics -Technology Landscape Analysis
4. Metabolomics - Market Landscape Analysis
5. Metabolomics - Technology Investment Potential
6. Metabolomics - Geographical Analysis
7. Competitive Landscape Analysis
8. Patent Analysis
9. Technology Analysis (Using Multi Criteria Decision Making) & Road Mapping
10 Analyst Insights & Recommendations
11 Company Profiles
• Ab Sciex
• Agilent Technologies
• Astrazeneca Plc
• Bio-Rad Laboratories
• Biocrates Life Sciences Ag
• Bruker Corporation
• Eisai Co. Ltd.
• Human Metabolome Technologies
• Metabolomic Technologies
• Metanomics Gmbh
• Nextgen Metabolomics
• Research Institute Of Chromatography
• Shimadzu Corporation
• Sidmap, Llc
• Stemina Biomarker
• Waters Corporation
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE